Journal
TRANSFUSION MEDICINE AND HEMOTHERAPY
Volume 36, Issue 3, Pages 189-198Publisher
KARGER
DOI: 10.1159/000216580
Keywords
Fetal DNA; Maternal plasma; SAFE
Categories
Funding
- European Commission for the Special Non-Invasive Advances in Fetal and Neonatal Evaluation (SAFE) [LSHB-CT-2004-503243]
Ask authors/readers for more resources
The availability of noninvasive prenatal diagnosis for the fetal RhD status (NIPD RhD) is an obvious benefit for alloimmunized pregnant women. This review gives information about the performance characteristics of current diagnostic technologies and recent promising proof-of-principle studies. Notably, during the past 3 years almost twice as much samples have been investigated with NIPD RhD compared with the studies from 1998 to 2005. Thus we have now a lot more information compared with the knowledge before 2006. There is no doubt that funding of the SAFE Network of Excellence (2004-2009) from the European Commission within the framework 6 program has massively increased the worldwide experience in NIPD RhD. In 2009 European funding has been stopped. Because of this large investment from public funding sources, it is now the duty of policy makers (scientific boards, patient groups, physician organizations, and health assurances) to discuss if targeted antenatal Rh prophylaxis should be introduced in German-speaking countries or which additional data are required to make a decision and how these additional studies should be funded.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available